ASH® 2025 Highlights: Presenter Vignette – Othman Al-Sawaf
Othman Al-Sawaf
MD
University Hospital of Cologne
1
Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.
